Precision Medicine in Obesity Research and Practice
Abstract
Obesity now already becomes a critical health problem in our country and the world. Since the genomic and biochemical technology has developed in the era of precision medicine, great progression has been achieved in the field of obesity research and clinical practice. Obesity is considered to be a series of diseases with high heterogeneity beyond expectations, which brings up the challenges on its diagnosis and classification. Predictive models for obesity remain absent in clinical practice and commercial use. It is important to further understand the roles of gastric hormones and related molecules, proteins in feeding and reward system, as well as gut microbiota in obesity and associated diseases. The diagnosis and treatment of obesity require further progression in molecular biology and genetics with fruitful investigation of precision medicine, which might help the clinical translation in future.
Keywords: Obesity, Precision medicine, Disease prediction, Genomics
Full Text:
PDFReferences
ZHAO W. ZHAI Y. HU J, et al. Economic burden of obesity-related chronic diseases in Mainland China. Obes Rev,2008,9(Suppl l):62-67.
HUANG C, YU H, KOPI-AN JP. Can China diminish its burden of non-communicable diseases and injuries by promoting health in its policies, practices, and incentives? Lancet,2014,384(9945) ;783-792.
NG M, FLEMING T, ROBINSON M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013; a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2014, 384(9945);766-781.
GARVEY WT, GARBER AJ, MECHANICK JI, et al. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract,2014 ,20(9) ;977-989.
OBAMA BH. Remarks by the President in State of the Union address. ( 2015-01-20 )[ 2016-11-30 ]. http://www. whitehouse. gov/the-press-office/2015/01/20/remarks-president-state-union-address-january-20-2015.
SLADEK R. ROCHELEAU G, RUNG J, et al. A genome- wide association study identifies novel risk loci for type 2 diabetes. Nature,2007,445(7130) ;881-885.
MEIGS JB, SHRADER P, SULLIVAN LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med.2008,359(21); 2208-2219.
PETERS T, AUSMEIER K. RUTHER U. Cloning of Fatso (Flo), a novel gene deleted by the Fused toes (Ft) mouse mutation. Mamm Genome, 1999 .10( 10); 983-986. SPEAKMAN JR. The ‘Fat Mass and Obesity Related’ (FTO) gene: Mechanisms of Impact on Obesity and Energy Balance. Curr Obes Rep,2015,4(1);73-91.
TUNG YC, YEO GS, O' RAHILLY S. Obesity and FTO; changing focus at a complex locus. Cell Metab,2014 ,20(5) : 710-718.
FRAYLING TM. TIMPSON NJ, WEEDON MN, et al. A common 4'ariant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science, 2007,316(5826); 889-894.
DINA C, MEYRE D, GALLINA S, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet,2007,39(6):724-726.
SCUTERI A, SANNA S, CHEN WM, et al. Genome-wide association scan shows genetic 4'ariants in the FTO gene are associated with obesity-related traits. PLoS Genet, 2007, 3 ( 7 ): el 15 [2016-11-30]. http://journals, plos. org/plosgenetics/article? id = 10. 1371/journal, pgen. 0030115. doi; 10. 1371/journal, pgen. 0030115.
LOOS RJ. Genetic determinants of common obesity and their value in prediction. Best Pract Res Clin Endocrinol Metab, 2012,26(2):211 -226.
ORDOVAS MUNOZ JM. Predictors of obesity; the "power” of the omics. Nutr Hosp.2013,28(Suppl 5):63-71.
LOPEZ-VILLAR E, MARTOS-MORENO GA, CHOWEN JA, et al. A proteomic approach to obesity and type 2 diabetes. J Cell Mol Med, 2015,19( 7): 1455-1470.
ZHANG A, SUN H, WANG X. Power of metabolomics in biomarker discovery and mining mechanisms of obesity. Obes Rev,2013.14(4):344-349.
MANCUSO P. The role of adipokines in chronic inflammation. Immunotargets Ther,2016(5);47-56[2016-11- 30]. https;//www.dovepress.com/the-role-of-adipokines-in-chronic-inflammation-peer-reviewed-article-ITT. doi: 10.2147/ITT. S73223.
KISH IDA K. FUNAHASHI T, SHIMOMURA I. Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab,2014 ,28( 1): 119-130.
MEEK TH. MORTON GJ. The role of leptin in diabetes: metabolic effects. Diabetologia,2016,59(5) :928-932.
FU Z, BERHANE F. FITE A, et al. Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity. Sci Rep,2014(4 ): 5013[2016-11-30]. http;//www. nature, com/ articles/srep05013. doi: 10. 1038/srep05013.
LI S, LIU D, LI L. et al. Circulating betatrophin in patients with type 2 diabetes; a meta-analysis. J Diabetes Res, 2016 (2016): 6194750[2016-11-30]. http://www.hindawi.com/journals/jdr/2016/6194750.doi: 10.1155/2016/6194750.
Refbacks
- There are currently no refbacks.
